Navigation Links
Department of Defense Exercises Options Under Contract for Nerve Agent Medical Countermeasure Program
Date:8/9/2012

ANNAPOLIS, Md., Aug. 9, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Department of Defense (DoD) has elected to exercise its option to accelerate funding for PharmAthene's rBChE nerve agent medical countermeasure program contingent on the achievement of key milestone activities.

"We believe this is a timely decision given the recent headlines about the potential threat of chemical weapons. PharmAthene is proud to be working in collaboration with the DoD to address this threat and provide innovative new solutions for our partners," remarked Eric I. Richman, President and Chief Executive Officer.  "We have enjoyed a productive collaboration with the DoD for many years, beginning with our first generation nerve agent countermeasure, Protexia® which completed a Phase I clinical study.  We are pleased to be continuing our partnership to advance a next generation platform to deliver a flexible and efficient manufacturing approach, and a cost-effective solution to our government client in support of this important national security initiative."

About rBChE
A recombinant form of human butyrylcholinesterase, rBChE, is a naturally occurring protein found in minute quantities in blood.  It functions as a natural bioscavenger, like a sponge, to absorb toxins such as organophosphorous poisons (nerve agents) and certain pesticides, before they cause irreversible neurological damage.  Nonclinical studies in animals suggest rBChE has the potential to provide significant protection against chemical nerve agent poisoning when administered prophylactically (prior to exposure to nerve agent) and also may increase survival when administered therapeutically (following nerve agent exposure).

PharmAthene is dev
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs
2. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
3. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
4. CEM President and CEO Delivers Commencement Address at the 2012 University of Texas at Austin Chemistry and Biochemistry Department Graduation
5. Covenant Security Services and the Department of Homeland Security Partner to Provide Nationwide Training on Active Shooter Awareness and Response
6. InVigor® Canola Supports the Michigan-Whitman Fire Department with More for Everyone Award
7. Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
8. JoVE partners with US government to publish cutting-edge defense research
9. National Defense Industrial Association (NDIA) Opens Registration For 2012 Biosurveillance Conference, Set For August 27-28 in Washington, D.C.
10. Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
11. National Defense Industrial Association's (NDIA) 2012 Biosurveillance Conference To Feature Keynote Speaker Laurie Garrett, Pulitzer Prize Winner and Bestselling Author
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 01, 2015 , ... A newly launched business plan contest will ask startup ... innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see ... a period of expert mentorship from a senior industry figure drawn from the Pistoia ...
(Date:7/1/2015)... IN (PRWEB) , ... July 01, 2015 , ... Apex ... 2015 BIO International Convention in Philadelphia, PA. , The presentation took place ... and outlined the plans for the development of APX3330 for the treatment of pancreatic ...
(Date:7/1/2015)... NEW YORK , July 1, 2015 /PRNewswire/ ... G ), a global leader in designing, ... the Aecus Innovation Award in recognition of their ... operational efficiencies in UCB,s global business services (GBS) ... acknowledge service providers and clients that work together ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... to take part in the first half of “Integrative Biotechnology,” an applied biotechnology ... established in summer 2014, this course combines students from both universities and is ...
Breaking Biology Technology:Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2
... Germany, April 29 , - Strong ... - Annual General Meeting Passes Dividend of EUR0.40 ... of Gerresheimer AG today passed an unchanged,dividend of EUR0.40 per share ... The Company finished the financial year 2008 with record results.,Gerresheimer achieved ...
... Data for Ipilimumab to be Presented -PRINCETON, N.J., April ... announced today that the following clinical abstracts for ipilimumab ... an anti-PD-1 antibody for cancer treatment, have been selected ... Meeting of the American Society of Clinical Oncology, being ...
... effort to provide technology to reduce healthcare-associated infections, ... device company, has demonstrated its patented ultra-fast (1 ... to protect hospital patients and medical professionals from ... It enables effective, frequent and instantaneous hygiene practice ...
Cached Biology Technology:2008 a Record Year for Gerresheimer 2Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 2Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 3Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 4Germgard's Ultra-Fast Hand Hygiene Solution Protects Against Deadly MRSA, C difficile, and Influenza Virus 2
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
(Date:6/16/2015)... June 16, 2015  With the increasing number and ... a top concern. The recent compromise of Federal ... for strong authentication within government agencies. HYPR ... one-time password (OTP) authenticator, has been submitted for testing ... Level 3 validation for tamper proofing. ...
(Date:6/15/2015)... , Jun. 15, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces that its ... showcased to media at Digital Experience! @ NYC June 18th. ... showcase of the latest innovation in technology to over 300 ... be held at the Metropolitan Pavilion in New ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... In roughly five to ten percent of breast cancer cases there ... genetic factors play a role here. Alterations in the genes known ... cancer these are responsible for roughly 25 percent of such ... are not attributable to mutations in BRCAI and BRCAII. We assume ...
... 13, 2008 Data published today in The Lancet ... fully bioabsorbable drug eluting stent for the treatment of ... driven target lesion revascularizations (re-treatment of a diseased lesion), ... cardiac events (MACE) in 30 patients out to one ...
... Crop scientists have cloned a gene that controls the ... mystery behind the huge morphological differences among edible fruits and ... plant development. The gene, dubbed SUN, is only the ... elongated shape of various tomato varieties, said Esther van der ...
Cached Biology News:Gene variant increases breast cancer risk 2The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent 2Crop scientists discover gene that controls fruit shape 2Crop scientists discover gene that controls fruit shape 3Crop scientists discover gene that controls fruit shape 4
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Recombinant Feline IL-12/IL-23 p40 (C-Terminus), CF...
Biology Products: